Get the Stockscreener App
78.59
1.69%
-1.35
After Hours:
78.54
-0.05
-0.06%
Kiniksa Pharmaceuticals International Plc stock is traded at $78.59, with a volume of 524.76K.
It is down -1.69% in the last 24 hours and up +1.25% over the past month.
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating cardiovascular diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and Vixarelimab. Geographically, the company earns maximum revenue from United States.
See More
Previous Close:
$79.94
Open:
$79.94
24h Volume:
524.76K
Relative Volume:
0.95
Market Cap:
$6.13B
Revenue:
$754.05M
Net Income/Loss:
$73.06M
P/E Ratio:
86.62
EPS:
0.9073
Net Cash Flow:
$164.23M
1W Performance:
-1.49%
1M Performance:
+1.25%
6M Performance:
+73.41%
1Y Performance:
+101.93%
1-Day Range:
$76.88
$80.34
1-Week Range:
$76.88
$82.98
52-Week Range:
$35.20
$82.98
Kiniksa Pharmaceuticals International Plc Stock (KNSA) Company Profile
Name
Kiniksa Pharmaceuticals International Plc
Sector
Phone
(781) 431-9100
Address
105 PICCADILLY, SECOND FLOOR, LONDON
Compare KNSA vs TAK, TEVA, HLN, ZTS, UTHR
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
KNSA
Kiniksa Pharmaceuticals International Plc
|
78.59 | 6.13B | 754.05M | 73.06M | 164.23M | 0.9073 |
TAK
Takeda Pharmaceutical Co Adr
|
19.67 | 62.84B | 29.91B | 1.30B | 3.49B | 0.4056 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
41.50 | 48.40B | 17.53B | 1.58B | 444.18M | 1.3457 |
HLN
Haleon Plc Adr
|
10.13 | 44.55B | 14.54B | 2.22B | 2.58B | 0.4871 |
ZTS
Zoetis Inc
|
79.38 | 32.80B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
533.12 | 22.87B | 3.17B | 1.29B | 1.01B | 27.09 |
Kiniksa Pharmaceuticals International Plc Stock (KNSA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-30-26 | Initiated | Wells Fargo | Overweight |
| Feb-19-26 | Initiated | Canaccord Genuity | Buy |
| Sep-29-25 | Initiated | TD Cowen | Buy |
| Mar-13-25 | Initiated | Citigroup | Buy |
| Sep-13-24 | Initiated | Jefferies | Buy |
| May-03-24 | Initiated | Wells Fargo | Overweight |
| Jun-29-20 | Reiterated | BofA Securities | Buy |
| Apr-01-20 | Initiated | BofA/Merrill | Buy |
| Mar-11-19 | Initiated | Barclays | Overweight |
| Dec-12-18 | Reiterated | Wedbush | Outperform |
| Jun-19-18 | Initiated | JMP Securities | Mkt Outperform |
View All
Kiniksa Pharmaceuticals International Plc Stock (KNSA) Latest News
Squarepoint Ops LLC Has $8.96 Million Stock Position in Kiniksa Pharmaceuticals International, plc $KNSA - MarketBeat
Megna Michael R Reduces Kiniksa Holdings to 29,062 Shares Following Sale and Other Transactions - Kalkine Media
Kiniksa Pharmaceuticals International PLC (KNSA) Shares Fall 3.2% -- What GF Score of 46 Tells Investors - GuruFocus
Kiniksa Pharmaceuticals COO Moat Ross Executes Significant Equity Transactions on September 1, 2026 - Kalkine Media
Kiniksa sets a live healthcare talk for Sept. 9 - Stock Titan
Kiniksa Pharmaceuticals CEO Sanj K Patel Reports RSU Vesting, Share Sale, and New Equity Grants - Kalkine Media
Kiniksa CFO Mark Ragosa Reports RSU Vestings, Tax Withholding Share Sale, and New Equity Grants - Kalkine Media
Kiniksa (NASDAQ: KNSA) grants 14,600 options and 3,650 RSUs to Michael Megna - stocktitan.net
Kiniksa (NASDAQ: KNSA) grants CMO options and RSUs - stocktitan.net
Kiniksa Pharmaceuticals International (NASDAQ:KNSA) CAO Michael Megna Sells 4,600 Shares - MarketBeat
Kiniksa Pharmaceuticals (KNSA) gives CEO new 10-year stock option grant - stocktitan.net
Kiniksa (KNSA) CEO gets new equity grants vesting over four years - stocktitan.net
Kiniksa Pharmaceuticals (KNSA) awards CFO new equity - stocktitan.net
Officer at Kiniksa (NASDAQ: KNSA) plans $369K stock sale - Stock Titan
Kiniksa Pharmaceuticals International, plc $KNSA Shares Sold by Braidwell LP - MarketBeat
Headlands Technologies LLC Purchases Shares of 18,161 Kiniksa Pharmaceuticals International, plc $KNSA - marketbeat.com
Kiniksa stock holds firm after a $243.6 million quarter - ad-hoc-news.de
Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Parabilis Medicines, Inc. (PBLS) Stock Price & News - Syfe
Kiniksa (KNSA) Earnings Reading: The EPS Result Is Below Expectation in the Current Update; Share Move: The Market Price Advances 1.03% at the CloseProfitability Analysis - vinanet.vn
Kiniksa Director Barry D Quart Donates 2,600 Class A Shares to Donor Advised Fund - Kalkine Media
Kiniksa (NASDAQ: KNSA) director gifts 2,600 shares to donor fund - stocktitan.net
Kiniksa (KNSA) Earnings Report: EPS Comes in Below Forecast in the Reported Period; Trading Move: Shares Move 2.88% Lower on the DayEarnings Revision Downgrade - vinanet.vn
Kiniksa Pharmaceuticals International PLC - TradingKey
Handelsbanken Fonder AB Makes New $1.34 Million Investment in Kiniksa Pharmaceuticals International, plc $KNSA - MarketBeat
Kiniksa Pharmaceuticals (NASDAQ:KNSA): A Compelling Affordable Growth Story - ChartMill
Kiniksa Pharmaceuticals International PLC (KNSA) Shares Surge 3. - GuruFocus
Bank of America Corp DE Boosts Stake in Kiniksa Pharmaceuticals International, plc $KNSA - MarketBeat
Kiniksa Highlights ARCALYST Growth as KPL-387 Advances Into Phase 3 - sharewise.com
Kiniksa Pharmaceuticals International, plc Class A Revenue Breakdown – BIVA:KNSA/N - TradingView
Kiniksa Highlights ARCALYST Growth as KPL-387 Advances Into Phase 3 - Yahoo Finance
KNSA: ARCALYST drives record growth as pipeline advances and patient access, awareness, and satisfaction rise - TradingView
Kiniksa Pharmaceuticals (KNSA) Stock Analysis: A Promising Outlook with 28% Potential Upside - DirectorsTalk Interviews
Kiniksa Pharmaceuticals (KNSA) Holds Near $76.53 as Bulls Eye $80.36 ResistanceBPI Bull Correction - vinanet.vn
Kiniksa Pharmaceuticals International, plc Class A Actuals & Estimates (NASDAQ:KNSA) - TradingView
Does Raised 2026 Revenue Guidance Change The Bull Case For Kiniksa Pharmaceuticals International (KNSA)? - simplywall.st
Kiniksa Pharmaceuticals International, plc $KNSA Stake Raised by The Manufacturers Life Insurance Company - MarketBeat
Kiniksa Pharmaceuticals to present at Canaccord Genuity Growth Conference on August 12, 2026 - Pluang
Kiniksa’s Aug. 12 fireside chat will stream live online - Stock Titan
Kiniksa Pharmaceuticals to Present at Canaccord Genuity 46th Annual Growth Conference - manilatimes.net
Kiniksa Pharmaceuticals to Present at Canaccord Genuity 46th Annual Growth Conference - GlobeNewswire
Kiniksa Pharmaceuticals International PLC (KNSA) Stock News Today - TradingKey
Kiniksa Pharmaceuticals International PLC (KNSA) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Kiniksa Pharmaceuticals International, plc $KNSA Shares Sold by Lazard Asset Management LLC - MarketBeat
Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
31,391 Shares in Kiniksa Pharmaceuticals International, plc $KNSA Bought by Financial Enhancement Group LLC - MarketBeat
Kiniksa Pharmaceuticals International, plc $KNSA Shares Bought by Janus Henderson Group PLC - MarketBeat
Kiniksa Pharmaceuticals International's (NASDAQ:KNSA) Strong Earnings Are Of Good Quality - 富途牛牛
Kiniksa Pharmaceuticals (KNSA) Stock Analysis: Unlocking A 33.5% Upside Potential - DirectorsTalk Interviews
Dimensional Fund Advisors LP Purchases 128,417 Shares of Kiniksa Pharmaceuticals International, plc $KNSA - MarketBeat
Kiniksa Pharmaceuticals International Plc Stock (KNSA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Kiniksa Pharmaceuticals International Plc Stock (KNSA) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Megna Michael R | Officer |
Sep 03 '26 |
Proposed Sale |
80.30 |
4,600 |
369,380 |
0 |
| Cole G Bradley | Director |
Jul 29 '26 |
Proposed Sale |
81.43 |
3,673 |
299,092 |
0 |
| Tessari Eben | Former Affiliate |
Jul 29 '26 |
Proposed Sale |
79.74 |
67,062 |
5,347,344 |
0 |
| Cole G Bradley | Director |
Jul 29 '26 |
Sale |
81.43 |
3,673 |
299,092 |
11,672 |
| Patel Sanj K | CHAIRMAN & CEO |
May 01 '26 |
Option Exercise |
30.93 |
48,565 |
1,502,115 |
48,565 |
| Paolini John F. | CHIEF MEDICAL OFFICER |
May 01 '26 |
Option Exercise |
10.36 |
58,424 |
605,273 |
124,047 |
| Paolini John F. | CHIEF MEDICAL OFFICER |
May 01 '26 |
Sale |
53.71 |
58,424 |
3,137,823 |
65,623 |
| Paolini John F. | Officer |
May 01 '26 |
Proposed Sale |
53.71 |
58,424 |
3,137,710 |
0 |
| Patel Sanj K | CHAIRMAN & CEO |
May 01 '26 |
Sale |
54.02 |
48,565 |
2,623,481 |
0 |
| Patel Sanj K | CHAIRMAN & CEO |
Apr 30 '26 |
Sale |
54.01 |
2,141 |
115,635 |
0 |
0.29%
2.79%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):